Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anixa BiosciencesANIX -1.40%29 EV-to-EBIT is -9.84 as of Jul. 22, 2026. GuruFocus rates ANIX with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 372 Biotechnology companies, Anixa Biosciences ranks worse than 268816.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Anixa Biosciences's Enterprise Value for the quarter that ended in Apr. 2026 was $87.02 Mil.
Anixa Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences EV-to-EBIT Related Terms
Anixa Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anixa Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's EV-to-EBIT falls into.
Anixa Biosciences's current Enterprise Value is $105.01 Mil.
Anixa Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (ANIX) has a EV-to-EBIT of -9.84 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #999999 out of 372 companies in the Biotechnology industry.
Is Anixa Biosciences' EV-to-EBIT too high?
Anixa Biosciences' current EV-to-EBIT is -9.84. Based on the distribution chart, Anixa Biosciences ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anixa Biosciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' EV-to-EBIT compare to BMEA and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #999999 out of 372 companies for EV-to-EBIT. This places Anixa Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 13.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.48, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anixa Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current EV-to-EBIT is -9.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current EV-to-EBIT of -9.84. The current EV-to-EBIT is -9.84. Anixa Biosciences' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current EV-to-EBIT is -9.84 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
29GF Score
Get the complete analysis for ANIX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
